Sector Expert: George Mack
Dr. George S. Mack is an analyst at consulting firm BioDecade where he is managing director. He performs biotechnology equity research for investors. His focus areas are oligonucleotide, cell and gene therapies. For a number of years he served as a consulting analyst at Decision Resources, and he has been published in Nature Medicine and Nature Biotechnology, the latter of which focuses on the science and business of biotechnology. At Nature Biotechnology he wrote lengthy main features on drug development in the areas of microRNA, systems biology, epigenetics and metastasis. He has been a contributor to financial publications that include Buyside and Wall Street Research, where he wrote for institutional investors. He is a contributor to The Life Sciences Report where he interviews biotechnology CEOs and sellside analysts. Dr. Mack is a 1970 graduate of the University of South Carolina in Columbia where he earned his BS degree in biology and a 1974 graduate of the Medical University of South Carolina in Charleston where he earned his DMD degree. He can be reached at email@example.com.
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way.
"RPís current minimalist market cap of under $US20 million and the fact that movement of these clinical studies into phase 2 and phase 3 could mean a very significant increase in share price."
George Mack, BioDecade